LAVA Therapeutics NV (LVTX) insider trading
Every open-market stock purchase and sale by LAVA Therapeutics NV executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- No open-market insider trades in the last 12 months.
- No open-market insider buys on record.
Last 12 months: insiders bought $0 (0 buys) and sold $0 (0 sales). Last close $1.74 on Nov 20, 2025.
Recent LVTX insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Nov 13, 2025 | Kapil Dhingra (Insider) | Sold (not open market) | — |
| Nov 13, 2025 | Kapil Dhingra (Insider) | Sold (not open market) | — |
| Nov 13, 2025 | Peter A Kiener (Insider) | Sold (not open market) | — |
| Nov 13, 2025 | Karen J Wilson (Insider) | Sold (not open market) | — |
| Nov 13, 2025 | Karen J Wilson (Insider) | Sold (not open market) | — |
| Nov 13, 2025 | James Noble (Insider) | Sold (not open market) | — |
| Nov 13, 2025 | Christy J. Oliger (Insider) | Sold (not open market) | — |
| Nov 13, 2025 | Fred M Powell (CFO) | Sold (not open market) | — |
| Nov 13, 2025 | Fred M Powell (CFO) | Sold (not open market) | — |
| Nov 13, 2025 | Mary E. Wadlinger (Insider) | Sold (not open market) | — |
| Nov 13, 2025 | Jay T. Backstrom (Insider) | Sold (not open market) | — |
| Nov 13, 2025 | Stephen A Hurly (CEO) | Sold (not open market) | — |
| Nov 13, 2025 | Stephen A Hurly (CEO) | Sold (not open market) | — |
Who's trading LVTX
- Mary E. Wadlinger, Insider: other filings, last Nov 13, 2025
- Fred M Powell, CFO: other filings, last Nov 13, 2025
- Karen J Wilson, Insider: other filings, last Nov 13, 2025
- Jay T. Backstrom, Insider: other filings, last Nov 13, 2025
- Kapil Dhingra, Insider: other filings, last Nov 13, 2025
- Stephen A Hurly, CEO: other filings, last Nov 13, 2025
- Peter A Kiener, Insider: other filings, last Nov 13, 2025
- James Noble, Insider: other filings, last Nov 13, 2025
- Christy J. Oliger, Insider: other filings, last Nov 13, 2025
Get free alerts when an insider at LAVA Therapeutics NV files a new trade →